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Abstract
Purpose—The aims of this study were to determine prevalence of and factors associated with 
any human papillomavirus (HPV) and vaccine-type HPV among young men after vaccine 
introduction, stratified by vaccination status.
Methods—Young men were recruited from clinical sites from 2013–2015, completed a survey, 
and were tested for 36 anogenital HPV types. We determined factors associated with > 1 HPV 
type among all participants, and vaccine-type HPV (HPV6, 11, 16, and/or 18) among all, 
vaccinated and unvaccinated participants, using multivariable regression.
Results—Mean age was 21.5 years and 26% had received at least one HPV vaccine dose. HPV 
prevalence was lower in vaccinated vs. unvaccinated young men (50.5% vs. 62.6%, p=.03). HPV 
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positivity was discordant by site. At both sites, 59.4% were positive for ≥ 1 HPV type and 26.0% 
for ≥ 1 4-valent vaccine type. In multivariable logistic regression, factors associated with ≥ 1 HPV 
type among all participants were frequency of oral sex (OR=1.80, 95% CI=1.00–3.24), recent 
smoking (OR=1.84, CI=1.17–2.90), and sexually transmitted infection history (OR=1.56, 
CI=1.02–2.38). Factors associated with vaccine-type HPV among all participants were White vs. 
Black race (OR=1.91, CI=1.10–3.34) and gonorrhea history (OR=2.52, CI=1.45–4.38); among 
vaccinated participants were private vs. Medicaid insurance (OR=5.6, CI=1.46–20.4) and private 
vs. no insurance (OR=15.9, CI=3.06–83.3); and among unvaccinated participants was gonorrhea 
history (OR=1.83, CI=1.03–3.24).
Conclusions—Anogenital HPV prevalence was high and vaccination rates low among young 
men two to four years after vaccine introduction, underscoring the urgency of increasing 
vaccination rates and vaccinating according to national guidelines.
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Introduction
Human papillomavirus (HPV) infects nearly 14 million people each year in the United 
States; almost half of infections occur in 15–24 year olds.(1) Infection may cause anogenital 
warts, anogenital cancers such as cervical cancer, and oropharyngeal cancers. The Centers 
for Disease Control and Prevention estimates that approximately 30,700 new cancers each 
year are attributable to HPV, including 11,600 cancers in men.(2)
Male HPV vaccination is effective, and could greatly decrease the burden of anogenital 
warts and cancers caused by HPV in men as well as decrease the disease burden in young 
women through herd immunity.(3, 4) In 2011, the Advisory Committee on Immunization 
Practices (ACIP) recommended routine vaccination of young men 11–21 years old and 
vaccination of young men 22–26 years old at high risk for HPV.(3) However, HPV vaccine 
coverage in young men is low. In 2015, only 49.8% of 13–17 year old men in the U.S. had 
received at least one dose of the vaccine and 28.1% had completed the series.(5)
Previous studies have demonstrated that the prevalence of any HPV among men ranges 
widely (1.3% to 72.9%) but is typically greater than 20%.(6) Surveillance studies have 
demonstrated a decrease in HPV in women and adult men after vaccine introduction.(7, 8) 
However, there are limited data available regarding the prevalence of HPV in adolescent 
men after vaccine introduction. Most studies have been conducted in adult men (i.e. men at 
least 18 years of age) or in young men who have sex with men (MSM).(9, 10) Furthermore, 
there are limited data regarding which factors are associated with HPV infection, and 
previous studies were conducted primarily in adults. These have demonstrated that factors 
associated with HPV infection include lifetime and recent number of sexual partners,(9–15) 
lack of circumcision,(11–14) inconsistent condom use,(12, 13, 15–17) smoking,(12, 15) and 
younger age.(11) Finally, little is known about concordance between anogenital sites in 
young men.(18)
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Information regarding the epidemiology and risk factors for HPV infection in adolescent and 
young adult men after vaccine licensing is essential for policy decisions, public health 
messaging, and prevention efforts. For example, HPV epidemiology is likely to change after 
HPV vaccine introduction, and current data regarding HPV prevalence in vaccinated and 
unvaccinated young men are important for guiding policies regarding immunization, 
decisions about vaccine financing, and the design of public health messages for clinicians 
and parents. In addition, risk factors for HPV may differ after vaccine introduction because 
vaccinated and unvaccinated men may differ in terms of demographic characteristics, 
behaviors, or other factors that are associated with their risk for HPV. Information about 
changing risk factors is important for public health messaging and designing interventions to 
prevent HPV post-vaccination. Therefore, the aims of this study were to: (1) determine the 
prevalence of anogenital HPV, and concordance between genital sites, in a diverse sample of 
13–26 year old sexually active adolescent and young adult men and (2) determine factors 
associated with a) any anogenital HPV (≥ 1 type) among all young men, and b) vaccine-type 
HPV among all, vaccinated, and unvaccinated young men. We hypothesized that prevalence 
of HPV would be high in this study sample, that having received at least one HPV vaccine 
dose would be associated with lower prevalence of vaccine-type HPV, and that factors 
associated with vaccine-type HPV would differ among vaccinated and unvaccinated men.
Methods
Young men 13–26 years old (N=400) were recruited between 2013 and 2015 from a 
hospital-based teen health center (THC) and a health department sexually transmitted 
disease (STD) clinic in Cincinnati, Ohio, U.S. Both sites serve a racially diverse, urban, and 
predominantly low income population. Men who had sexual contact (genital-oral or genital-
genital with male or female partners) were eligible to participate. All vaccinated men had 
received the 4-valent vaccine. Men were recruited using a sequential sampling strategy (all 
eligible men were invited to participate): 91% of those approached agreed to participate. The 
study was approved by the Institutional Review Boards of the hospital and the health 
department, and written informed consent was obtained from participants. Participants 
completed a survey instrument in English or Spanish assessing sociodemographic 
characteristics, HPV and HPV vaccine knowledge, vaccination history, substance use 
history, and sexual behaviors. The survey was developed and validated in similar 
populations: details are described in previous manuscripts.(19–21)
Three separate genital swabs (penile, including coronal sulcus, glans penis, and shaft of the 
penis, as well as scrotal) and one perianal/anal swab were collected from each male 
participant for HPV DNA testing using previously-described procedures.(22) Swabs were 
pre-moistened with sterile saline, placed immediately into tubes containing 1 mL of Digene 
Specimen Transport Medium (STM, Qiagen, Germantown, MD), and stored at −80°C. The 
three penile/scrotal samples were combined to produce one genital DNA extract per 
participant, and the perianal/anal sample was analyzed separately. This method has been 
shown to optimize HPV detection among men and to result in reproducible detection of 
genital HPV in men, while achieving cost savings.(22, 23) Samples were analyzed for HPV 
genotypes using the Roche Linear Array Assay, a polymerase chain reaction amplification 
technique that uses an L1 consensus primer system and reverse-line blot detection strip to 
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identify 36 different HPV genotypes (Roche Molecular Systems, Alameda, CA).(24) The 
Roche Linear Array tests for 37 high-risk and low-risk genotypes (6, 11, 16, 18, 26, 31, 33, 
35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 
81, 82, 83, 84, IS39, and CP6108): IS39 has been reclassified as a subtype of HPV82, so the 
test detects 36 distinct genotypes. The HPV test results from genital (penile and scrotal) and 
perianal/anal sites were analyzed separately for descriptive analyses, but were combined for 
univariable and multivariable analyses due to insufficient power to analyze type-specific 
HPV prevalence by site in the multivariable analyses.
The primary outcome variables for this study were any HPV (≥ 1 type) and 4-valent vaccine-
type HPV (HPV6, 11, 16, and/or 18). Independent variables included vaccination status, 
number of vaccine doses, demographic factors (age, race, ethnicity, insurance status, type of 
insurance), recruitment site (THC vs. STD clinic), sexual behaviors (lifetime number of 
female and male partners; recent number of female and male partners; recent number of new 
female and male partners; age of first sexual intercourse with male and female partners; 
recent condom use with men and women; condom use at last sexual intercourse; recent 
history of giving or receiving oral sex), sexual orientation, substance use (recent and lifetime 
cigarette smoking, recent and lifetime marijuana smoking), and history of other sexually 
transmitted infections. These independent variables were chosen based on biological 
plausibility and/or because they have been associated with HPV and other STIs in previous 
studies.(10, 11, 13–17, 25, 26)
Any HPV, type-specific HPV (types included in the 4-valent and 9-valent vaccines, non-
vaccine-type, high-risk, HPV16/18, and HPV6, 11, 16 and 18), and vaccination rates were 
determined using descriptive statistics. HPV results were then stratified by site (penile/
scrotal vs. perianal/anal), age (13–21 vs. 22–26 years), and vaccination status. We also 
examined the association between number of vaccine doses and vaccine-type HPV using 
logistic regression.
Associations between independent and outcome variables were determined using chi-square, 
Fisher’s exact and Wilcoxon rank-sum tests. Independent variables associated at p<0.10 with 
outcome variables in univariable analyses were checked for multicollinearity and eliminated 
from multivariable analysis when appropriate. Variables associated with four outcomes (≥ 1 
HPV type among all participants, and vaccine-type HPV among all, vaccinated, and 
unvaccinated participants) at p<0.10 in univariable analysis were included in four 
multivariable logistic regression models. Stepwise variable selection was used and variables 
associated with the outcomes at p<0.05 were retained in the final models.
Results
Participant characteristics, vaccination rates, and HPV prevalence
Participants’ mean age was 21.5 years (20.8% 14–18 years, 28% 19–21 years, 51.3% 22–26 
years), 69% were Black, 2.5% were Hispanic, 10% were MSM, 50% reported an STI 
history, and 4% reported being HIV positive. Most participants (66.5%) were recruited from 
the STD clinic, 24.3% had private insurance, and 27.5% had Medicaid (public) insurance. 
Overall, 26.0% had received at least one HPV vaccine dose, and 12.3% had received all 3 
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HPV vaccine doses. Data addressing the first aim of the study are shown in Table 1. Among 
all participants, 59.4% were positive for ≥ 1 HPV type, 26% for ≥ 1 4-valent vaccine type, 
18.9% for HPV16, and 4.5% for HPV18 (Table 1). HPV prevalence in vaccinated vs. 
unvaccinated young men was: any HPV (50.5% vs. 62.6%, p=.03), 4-valent vaccine-type 
HPV (20.4% vs. 27.9%, p=.13), 9-valent vaccine-type HPV (25.2% vs. 34.4%, p=.09), non-
vaccine-type HPV (37.9% vs. 54.4%, p=.004), high-risk HPV (44.7% vs. 49.3%, p=.42), 
high-risk non-vaccine-type HPV (31.1% vs. 37.4%, p=.25), HPV16/18 (18.5% vs. 24.8%, 
p=.18), HPV6 (1.9% vs. 4.4%, p=.26), HPV11 (0% vs. 1.7%, p=.18), HPV16 (14.6% vs. 
20.4%, p=.19), and HPV18 (4.9% vs. 4.4%, p=.86). The association between number of 
vaccine doses and vaccine-type HPV among vaccinated men was not significant: 1 vs. 3 
doses (odds ratio [OR] 0.99, 95% confidence interval [CI] 0.33–2.96) and 2 vs. 3 doses (OR 
0.60, 95% CI 0.17–2.12). Among participants positive for anogenital HPV, results were 
generally discordant when stratified by site (penile/scrotal vs. perianal/anal). For example, 
among the 75 men positive for HPV16, 39 (52%) were positive at the genital site only, 27 
(36%) at the anal site only, and 9 (12%) at both sites. (Table 1). There were no statistically 
significant differences in HPV by age.
Factors associated with ≥ 1 HPV type among all young men
In univariable analyses the following factors were significantly associated with positivity for 
≥ 1 HPV type (Table 2): vaccination status, recruitment from STD clinic vs. THC, higher 
lifetime number of female partners, higher number of new male partners in the past 3 
months, inconsistent condom use, higher frequency of oral sex in the past 3 months, history 
of STI, lifetime smoking, recent smoking, and recent marijuana use. In multivariable logistic 
regression the variables independently associated with HPV positivity were higher frequency 
of oral sex in the past 3 months, recent smoking, and history of STI (Table 3).
Factors associated with vaccine-type HPV among all, vaccinated, and unvaccinated young 
men
In univariable analysis, the factors significantly associated with vaccine-type HPV among all 
young men included: ever had sexual intercourse with a male partner, homosexual or 
bisexual preference, higher number of male partners (any and new) in the past 3 or 12 
months, and history of gonorrhea (Table 4). Although unvaccinated men were more likely 
than vaccinated men to be positive for vaccine type HPV, the difference was not statistically 
significant. In multivariable logistic regression, factors independently associated with 
vaccine-type HPV among all participants were White vs. Black race and a history of 
gonorrhea (Table 5). In univariable analyses, factors significantly associated with vaccine-
type HPV among vaccinated young men included: private (vs. Medicaid or no) insurance, 
having had sexual intercourse with a male partner, higher number of male partners in the 
past 12 months, having a male main sexual partner, and identification as bisexual or 
homosexual vs. heterosexual (Table 4). In multivariable logistic regression, factors 
independently associated with vaccine-type HPV among vaccinated young men were private 
vs. Medicaid insurance and private vs. no insurance (Table 5). In univariable analyses, 
factors significantly associated with vaccine-type HPV in unvaccinated young men included: 
history of gonorrhea, history of herpes, and higher number of new male partners in the past 3 
months (Table 4). In multivariable logistic regression analyses one factor was independently 
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associated with vaccine-type HPV among unvaccinated participants: history of gonorrhea 
(Table 5).
Discussion
In this study, we examined the prevalence of and factors associated with any HPV infection 
and vaccine-type HPV infection, as well as HPV type concordance between anogenital sites, 
in a diverse sample of adolescent and young adult men. The study provides novel data about 
HPV epidemiology in young men, two to four years after HPV vaccination was 
recommended for young men in the U.S.
As hypothesized, the prevalence of HPV was high in this study sample: 59% were positive 
for at least one HPV type, 26% for at least one 4-valent vaccine-type HPV, 23.2% for 
HPV16/18, and 18.9% for HPV16. Prevalence did not differ by age. In a study of HIV-
seronegative adult MSM, Goldstone et al. reported a prevalence of 48.1% for any HPV, 19% 
for HPV 16/18, and 13.7% for HPV 16.(10) In a study of 18–44 year-old men, Giuliano et 
al. demonstrated a prevalence of 52.8 % for ≥ 1 HPV, 10.0% for HPV 16/18, and 8.6% for 
HPV 16.(27) Furthermore, Burchell et al. found a prevalence of 55.9% for any HPV, 20.2% 
for HPV 16/18, and 16.4% for HPV 16 in a study of HPV transmission and prevalence 
among new heterosexual couples.(28) The prevalence of any HPV in our study was similar 
to what was reported in these studies, and the prevalence of HPV16 and/or HPV18 was even 
higher, despite the fact that a small proportion of the men in our study were MSM and they 
were recruited after vaccine introduction.
Although limited data have been published regarding HPV prevalence among men younger 
than 18 years, two studies have examined HPV incidence in this age group. In a study of 16–
20 year-old men who have sex with men, the incidence rate for any anal HPV infection was 
57 and for vaccine-type anal HPV was 33 cases per 100 person-years, and in an study of 16–
24 year-old men, the incidence rate of vaccine-type HPV was 9 cases per 100 person-years.
(29, 30) Together with our findings of high HPV prevalence in young men, these data 
suggest that higher vaccination rates are needed to achieve the benefits of vaccination.
We recruited a sample of young women during the same time period, with similar 
demographic characteristics and from comparable clinical sites. In young women, the 
prevalence of ≥ 1 HPV type was higher (67.4%), but the prevalence of 4-valent vaccine-type 
HPV much lower (8.7%) as was the prevalence of HPV 16/18 (7.3%).(7) The higher 
vaccine-type HPV prevalence in young men vs. women is likely due to the five-year lag 
between vaccine recommendations in women and men, and the resulting higher rates of 
vaccination in women (71.3% in women vs. 26% in men).
We found fairly low concordance in type-specific HPV by site: most HPV-infected young 
men were positive only at the genital or anal sites, but not at both sites. Although few studies 
are available for comparison, in a study of HIV-infected MSM, Welling et al. demonstrated 
that anal HPV was significantly associated with a type-concordant penile infection and 
penile infection was associated with a type-concordant anal infection.(31) Kofoed et al. 
found a 78.1% concordance between anal and genital wart HPV types among men and 
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women with genital warts.(32) Blas et al. noted a higher rate of anal HPV compared to HPV 
at other genital sites among adult MSM.(33) The relatively high discordance found in our 
study could be due to sexual behaviors: most study participants practiced only vaginal sex 
with women, and had never had anal sex with a women or man. Other factors that may 
influence concordance rates include HPV sampling and detection methods and study 
population characteristics.
Recent studies have demonstrated that introduction of HPV vaccines greatly decreases HPV 
prevalence.(34) Young men participating in this study who were vaccinated, compared to 
those who were unvaccinated, had a significantly lower prevalence of any HPV infection 
(50.5% vs. 62.6%). Although those who were vaccinated compared to those who were 
unvaccinated also had a lower prevalence of vaccine-type HPV, the differences were not 
statistically significant. This finding may be explained by the fact that many of these young 
men had not been fully vaccinated and may have acquired vaccine-type HPV prior to 
vaccination: prophylactic HPV vaccines are most effective if given prior to sexual initiation. 
It is also possible that we had insufficient power to detect differences in vaccine-type HPV 
by vaccination status due to the relatively small number of vaccinated men who were 
infected with vaccine-type HPV (N=21). We are conducting surveillance studies in this 
population, and expect that we will observe a protective effect in young men with a larger 
number of participants and when vaccination rates are higher. Vaccination rates in this 
sample were described in more detail in a previous publication,(35) and differed 
substantially by age: 69.9% of 13–18 year-olds and 4.9% of 22–26 year-olds received at 
least one dose.(35) These findings are comparable to those of national studies, which 
demonstrated that 49.8% of 13–17 year olds and 8.2% of 19–26 year-olds had received at 
least one dose.(5, 36) The results support the importance of effective, comprehensive 
interventions to improve vaccination rates among young men. The evidence base for such 
interventions is growing, and includes addressing healthcare systems issues (reducing cost, 
improving reimbursement, enhancing vaccination infrastructure, optimizing delivery 
systems), promoting national recommendations, reducing missed opportunities to administer 
vaccines, strengthening clinician recommendations for the vaccine, increasing parental and 
adolescent acceptance of vaccination, and offering vaccination in alternative settings as 
noted in a recent President’s Cancer Panel Report (http://deainfo.nci.nih.gov/advisory/pcp/
annualReports/HPV/#sthash.6fNlYd6p.dpbs).
Factors associated with HPV infection in these young men included higher frequency of 
recent oral sexual encounters, recent smoking, and history of an STI. The association 
between oral sex and anogenital HPV may be due to direct oral-genital transmission or be a 
marker of higher exposure to sexual behaviors that would put young men at risk for HPV 
transmission. In a recent systematic review and meta-analysis of oral HPV infection in men 
who have sex with men, the authors found that while a proportion of men were concordant 
for oral and anogenital HPV, type-specific concordance between oral and anogenital sites 
was rare.(37) Given that HPV-associated oropharyngeal cancer incidence rates are rising, 
especially in men, a better understanding of oral-genital transmission patterns in young men, 
the natural history of oral HPV in men, and the pathogenesis of HPV-associated 
oropharyngeal cancer will be important to design interventions that will reverse this trend.
(38) Several recent studies have confirmed an association between smoking and HPV 
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infection in men.(12, 15) Furthermore, Schabath et al demonstrated that current smoking 
was associated with higher incidence of genital HPV infection.(39) In MSM, smoking is 
associated with a higher viral load of high-risk HPV types, abnormal anal cytology, and an 
increased risk for anal cancer.(40) Given the strong association between number of sexual 
partners and HPV infection,(11–15) it is not surprising that history of an STI is associated 
with HPV infection.
Finally, we identified factors associated with prevalent vaccine-type HPV by vaccination 
status, and as hypothesized, factors differed among vaccinated and unvaccinated men. 
Moreira et al. examined risk factors for incident vaccine-type HPV among heterosexual 
adolescent and young adult men, and found that that higher number of sexual partners, less 
frequent condom use, and living in Africa were associated with incident HPV.(30) In our 
study, sexual behaviors (including male sexual partners and number of male partners) were 
associated with prevalent vaccine-type HPV in univariable, but not multivariable analyses. 
Among all participants, White race and history of gonorrhea were associated with vaccine-
type HPV; among vaccinated participants, private insurance was associated with vaccine-
type HPV; and among unvaccinated participants, history of gonorrhea was associated with 
vaccine-type HPV. Those participants recruited from the STD clinic, compared to those 
recruited from the THC, were older, more likely to be White, more likely to have private 
insurance, and less likely to have been vaccinated. They were also more likely to be positive 
for HPV. These factors may explain why White race and private insurance were associated 
with HPV infection. A history of gonorrhea may be a marker for riskier sexual behaviors 
that could increase HPV acquisition. The fact that we could not identify a set of modifiable 
risk factors for HPV or vaccine-type HPV suggests that it is challenging to determine who is 
at risk for HPV, underscoring the importance of primary prevention through vaccination and 
counseling about limiting sexual partners and consistent condom use.
There are several limitations to this study. The design is cross-sectional; therefore, we cannot 
draw conclusions from the results about causality. Behaviors were self-reported which may 
limit validity. Participants were recruited from clinical sites, which diminishes the 
generalizability of the findings; it is possible that HPV prevalence is higher in those not 
accessing clinical care. The sample size was relatively small, limiting our ability to detect 
significant associations between independent variables and HPV infection. Although we 
used established methods for anogenital sampling and reliable HPV DNA testing methods, 
as noted in the Methods section, there are limitations to all HPV testing methods and it is 
possible that there were false positives or false negatives. Furthermore, we only tested HPV 
at one point in time. Finally, we tested a limited number of HPV DNA genotypes, so it 
should be noted that throughout the manuscript when we refer to “any HPV,” this actually 
signifies any HPV among the types detected by the Roche Linear Array test.
Conclusion
Any and vaccine-type HPV prevalence were high and vaccination coverage was low among 
young men in this study sample, two to four years after the vaccine was introduced. 
Furthermore, our analyses did not identify a set of risk factors associated with vaccine-type 
HPV that could be targeted in interventions. Our findings emphasize the importance of 
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primary prevention of HPV through increasing vaccination rates in young men and 
vaccinating before sexual initiation. The findings also suggest that interventions to promote 
STI prevention such as limiting sexual partners and using condoms consistently will be 
important, though challenging.
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Implications and Contributions
Few studies have examined the prevalence and risk factors for HPV and concordance 
between genital sites in adolescent males after vaccine introduction. This study 
demonstrates that HPV prevalence was high and vaccination rates low among young men 
2–4 years after vaccine introduction, underscoring the importance of vaccination 
according to national guidelines.
Chandler et al. Page 12
J Adolesc Health. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chandler et al. Page 13
Ta
bl
e 
1
Ty
pe
-s
pe
ci
fic
 H
PV
 p
re
v
al
en
ce
 b
y 
an
at
om
ic
al
 si
te
H
PV
 p
re
v
a
le
nc
e,
 a
ny
 si
te
N
 (%
)
H
PV
 p
re
v
a
le
nc
e,
 si
te
-s
pe
ci
fic
N
 (%
)
H
PV
 T
yp
es
G
en
ita
l a
nd
/o
r a
na
l1
G
en
ita
l o
nl
y
A
na
l o
nl
y
Bo
th
 g
en
ita
l a
nd
 a
na
l
N
ei
th
er
 g
en
ita
l n
or
 a
na
l
≥ 
1
23
6 
(59
.4)
13
2 
(35
.0)
40
 (1
0.6
)
64
 (1
7.0
)
14
1 
(37
.4)
In
cl
ud
ed
 in
 th
e 
4-
va
le
nt
 v
ac
ci
ne
2
10
3 
(26
.0)
50
 (1
3.3
)
32
 (8
.5)
21
 (5
.6)
27
2 
(72
.5)
In
cl
ud
ed
 in
 th
e 
9-
va
le
nt
 v
ac
ci
ne
3
12
7 
(32
.0)
68
 (1
8.1
)
32
 (8
.5)
27
 (7
.2)
24
9 
(66
.2)
N
on
-v
ac
ci
ne
4
19
9 
(50
.1)
12
6 
(33
.5)
27
 (7
.2)
46
 (1
2.2
)
17
7 
(47
.1)
H
ig
h-
ris
k5
19
1 
(48
.1)
10
8 
(29
.0)
43
 (1
1.5
)
40
 (1
0.7
)
18
4 
(49
.1)
H
ig
h-
ris
k,
 n
on
-v
ac
ci
ne
6
14
2 
(35
.8)
94
 (2
5.1
)
25
 (6
.7)
23
 (6
.1)
23
2 
(62
.0)
H
ig
h-
ris
k,
 in
cl
ud
ed
 in
 th
e 
va
cc
in
e7
92
 (2
3.2
)
43
 (1
1.5
)
35
 (9
.4)
14
 (3
.7)
28
2 
(75
.4)
H
PV
 6
15
 (3
.8)
9 
(2.
4)
2 
(0.
5)
4 
(1.
1)
35
9 
(96
.0)
H
PV
 1
1
5 
(1.
3)
0 
(0)
3 
(0.
8)
2 
(0.
5)
36
8 
(98
.7)
H
PV
 1
6
75
 (1
8.9
)
39
 (1
0.4
)
27
 (7
.2)
9 
(2.
4)
29
9 
(80
.0)
H
PV
 1
8
18
 (4
.5)
4 
(1.
1)
9 
(2.
4)
5 
(1.
3)
35
5 
(95
.2)
1 G
en
ita
l r
ef
er
s t
o 
pe
ni
le
/sc
ro
ta
l s
am
pl
es
 a
nd
 a
na
l r
ef
er
s t
o 
pe
ria
na
l/a
na
l s
am
pl
es
2 I
nc
lu
de
d 
in
 th
e 
4-
va
le
nt
 v
ac
ci
ne
: H
PV
6,
 1
1,
 1
6,
 an
d/
 o
r 1
8
3 I
nc
lu
de
d 
in
 th
e 
9-
va
le
nt
 v
ac
ci
ne
: H
PV
6,
 1
1,
 1
6,
 1
8,
 3
1,
 3
3,
 4
5,
 5
2,
 an
d/
or
 5
8
4 N
on
-v
ac
ci
ne
: a
ny
 H
PV
 ty
pe
s d
et
ec
te
d 
ex
ce
pt
 fo
r H
PV
6,
 1
1,
 1
6,
 an
d/
or
 1
8
5 H
ig
h-
ris
k:
 H
PV
16
, 1
8,
 2
6,
 3
1,
 3
3,
 3
5,
 3
9,
 4
5,
 5
1,
 5
2,
 5
3,
 5
6,
 5
8,
 5
9,
 6
7,
 6
8,
 7
0,
 7
3,
 8
2,
 an
d/
or
 8
9
6 H
ig
h-
ris
k,
 n
on
-v
ac
ci
ne
: a
ll 
hi
gh
-ri
sk
 ty
pe
s o
th
er
 th
an
 H
PV
16
 an
d 
18
7 H
ig
h 
ris
k,
 in
cl
ud
ed
 in
 th
e 
va
cc
in
e:
 H
PV
16
, 1
8
J Adolesc Health. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chandler et al. Page 14
Table 2
Factors significantly associated with positivity for ≥ 1 HPV type among all participants: Results of univariable 
analyses1
N (%) P Value2
Vaccination status 0.03
 Vaccinated 52 (50.5)
 Unvaccinated 184 (62.6)
Enrollment site 0.0001
 Teen Health Center 58 (43.9)
 STD Clinic 178 (67.2)
Lifetime number of female partners 0.01
 0 16 (61.5)
 1 8 (32.0)
 2–5 40 (50.0)
 6–10 66 (67.4)
 11–20 54 (60.0)
 ≥ 21 48 (64.9)
Number of new male partners in past 3 months 0.04
 0 219 (58.4)
 1 9 (64.3)
 ≥ 2 8 (100)
Condom use during anal sex with female partners, past 3 months 0.046
 Mostly/Always 5 (33.3)
 Never/Occasionally 23 (63.9)
Had oral sex in past 3 months 0.01
 0 time 33 (47.1)
 1 time 13 (41.9)
 2–5 times 99 (65.1)
 ≥ 5 times 90 (62.9)
Smoked at least 100 cigarettes 0.03
(5 packs) in lifetime
 No 144 (55.4)
 Yes 86 (67.2)
Number of days smoked 0.001
cigarettes in the last 30 days
 0 days 136 (53.5)
 1+ days 100 (69.9)
Number of days smoked 0.049
marijuana in the last 30 days
 Never smoked 44 (52.4)
 0 days 57 (53.8)
 1+ days 135 (65.2)
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N (%) P Value2
History of a sexually transmitted infection 0.004
 No 103 (52.3)
 Yes 133 (66.5)
1Only those independent variables significantly associated with HPV are shown in the table. The complete list of independent variables is as 
follows: age, race, ethnicity, recruitment site, insurance status, type of insurance, lifetime number of female and male partners, recent number of 
female and male partners, recent number of new female and male partners, age of first sexual intercourse with male and female partners, recent 
condom use (with men and women; if men, with receptive or insertive anal sex), condom use at last sexual intercourse, recent history of giving or 
receiving oral sex, sexual orientation, last time genitals were washed, lifetime and recent cigarette smoking, lifetime and recent marijuana smoking, 
STI history.
2
P value derived from a chi-square test
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Table 3
Factors significantly associated with positivity for ≥ 1 HPV type among all participants: Results of 
multivariable analysis1
Variable Categories AOR2 95% CI3
Had oral sex in the past 3 months 2–5 vs. 0 days (ref.) 1.80 1.00–3.24
Smoked cigarettes in the past 30 days ≥ 1 vs. 0 days (ref.) 1.84 1.17–2.90
History of a sexually transmitted infection Yes vs. no (ref.) 1.56 1.02–2.38
1Additional variables included in the model were number of lifetime female partners, number of new male partners in the past 3 months, history of 
anal sex with a female partner, condom use during anal sex with a female partner in the past 3 months, and recent marijuana use
2AOR= Adjusted Odds Ratio
3CI= confidence interval
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Table 4
Factors significantly associated with 4-valent vaccine-type HPV in all, vaccinated, and unvaccinated young 
men: Results of univariable analyses
Vaccine Type HPV
N (%) P-Value
1
All Young Men
Vaccination Status 0.13
 Vaccinated 21 (20.4)
 Unvaccinated 82 (27.9)
Ever had sex with a male partner 0.02
 No 86 (24.2)
 Yes 17 (41.5)
Sexual orientation 0.009
 Heterosexual 86 (24.2)
 Homosexual 10 (32.3)
 Bisexual 5 (71.4)
Number of male partners, past 3 months 0.01
 0 86 (23.9)
 1 9 (45.0)
 ≥ 2 8 (47.1)
Number of new male partners, past 3 months 0.009
 0 93 (24.8)
 1 4 (28.6)
 ≥ 2 6 (75)
Number of male partners, past 12 months 0.01
 0 86 (24.0)
 1 4 (33.3)
 ≥ 2 13 (50.0)
Number of new male partners, past 12 months 0.02
 0 88 (24.1)
 1 5 (41.7)
 ≥ 2 10 (50.0)
Ever had gonorrhea 0.006
 No 72 (22.9)
 Yes 31 (37.8)
Vaccinated Young Men
Health insurance plan 0.0009
 None/Not sure 3 (8.1)
 Medicaid 11 (20.4)
 Private 7 (58.3)
Ever had sex with a male partner 0.01
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Vaccine Type HPV
N (%) P-Value
1
 No 15 (16.7)
 Yes 6 (46.2)
Number of male partners, past 12 months 0.02
 0 15 (16.7)
 1 1 (20.0)
 ≥ 2 5 (62.5)
Number of new male partners, past 12 months 0.04
 0 16 (17.4)
 1 2 (33.3)
 ≥ 2 3 (60.0)
Gender of main sexual partner 0.01
 Female 11 (15.5)
 Male 6 (54.6)
 No main partner 4 (19.1)
Sexual orientation 0.02
 Heterosexual 15 (16.9)
 Homosexual 3 (30.0)
 Bisexual 3 (75.0)
Unvaccinated Young Men
History of gonorrhea 0.04
 No 56 (24.9)
 Yes 26 (37.7)
History of genital herpes
 No 79 (27.2) 0.03
 Yes 3 (75.0)
Number of new male partners, past 3 months 0.04
 0 75 (26.9)
 1 2 (22.2)
 ≥ 2 5 (71.4)
1
P value derived from a chi-square test or Fisher’s exact test
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Table 5
Factors significantly associated with vaccine-type HPV in all, vaccinated, and unvaccinated participants: 
results of multivariable analyses1
Variable Categories Contrasted AOR2 95% CI3
Model 1: All Participants
Race White vs. Black (ref.) 1.91 1.10–3.34
History of gonorrhea Yes vs no (ref.) 2.52 1.45–4.38
Model 2: Vaccinated Participants
Insurance Plan Private vs. Medicaid (ref.) 5.46 1.46–20.4
Private vs. no health insurance (ref.) 15.9 3.06–83.3
Model 3: Unvaccinated Participants
History of gonorrhea Yes vs. no (ref.) 1.83 1.03–3.24
1Additional variables included in model 1: insurance plan, number of new male partners in the past 3 months, and sexual preference; model 2: 
insurance status, ever had sex with male, last sex with a female, history of gonorrhea, number of new male partners in 3 months, number of male 
partners in 12 months; model 3: number of new male partners in 3 months, history of herpes
2AOR= adjusted odds ratio
3CI= confidence interval
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